When cervical cancer is beyond curative treatment with surgery or radiation therapy, the prognosis is poor and palliation is the primary objective. Early prospective studies identified cisplatin as an active drug for advanced, metastatic, or recurrent cervical cancer, and results with other platinum analogs seemed inferior to cisplatin. Several phase III trials have established the combination of cisplatin plus paclitaxel as standard therapy for comparison. Using pooled data from 3 Gynecologic Oncology Group (GOG) phase III studies, a predictive model was developed to better identify patients who are unlikely to respond to cisplatin-containing chemotherapy. The GOG is currently developing a phase III trial to investigate the impact of bevacizumab and a regimen containing topotecan instead of cisplatin in combination with paclitaxel chemotherapy and also to externally validate the predictive model. This study has the potential to radically change standard care for cervical cancer chemotherapy. Furthermore, if the predictive model is upheld, then patients with high risk factors for treatment failure may be directed to chemotherapy regimens that do not include cisplatin or to investigational trials.
Harold J. Burstein
Pablo Maroto, Georgia Anguera, Juan Maria Roldan-Romero, Maria Apellániz-Ruiz, Ferran Algaba, Jacqueline Boonman, Mark Nellist, Cristina Montero-Conde, Alberto Cascón, Mercedes Robledo, and Cristina Rodríguez-Antona
mTOR inhibitors are used to treat renal cell carcinoma (RCC). Treatment response is variable and appears to correlate with genetic alterations that activate mTOR signaling. Recently, everolimus was suggested to be more effective than sunitinib in chromophobe RCC (chRCC), a tumor with frequent mTOR pathway defects. This report presents the genomic and functional characterization of a metastatic chRCC that showed complete response at metastatic sites and 80% reduction in primary tumor size upon temsirolimus treatment. After surgery, the patient remained disease-free for 8 years after temsirolimus therapy. Whole-exome sequencing (WES) revealed 2 somatic variants in TSC2, a critical negative regulator of mTOR: a splicing defect (c.5069-1G>C) and a novel missense variant [c.3200_3201delinsAA; p.(V1067E)]. In vitro functional assessment demonstrated that the V1067E substitution disrupted TSC2 function. Immunohistochemistry in the tumor tissues revealed increased phosphorylated S6 ribosomal protein, indicating mTOR pathway activation. In conclusion, WES revealed TSC2 inactivation as the likely mechanism for this extraordinary response to temsirolimus. These findings support high efficacy of mTOR inhibitors in a subset of patients with chRCC and propose sequencing of mTOR pathway genes to help guide therapy.
Richard L. Theriault
Breast cancer frequently metastasizes to bone. Metastases result in skeletal morbidity including pathologic fractures, the need for radiation or surgery to bone, spinal cord compression and hypercalcemia. The pathophysiology of bone destruction is related to activation of osteoclasts by tumor-derived and bone marrow microenvironmental factors. One prominent osteoclast–activating factor associated with breast cancer is parathyroid hormone-related peptide (PTHrP). Bisphosphonates have been shown to impair osteoclast activity by decreasing recruitment from the monocyte macrophage cell line, inhibiting osteoclast function at the bone site and causing osteoclasts to undergo apoptosis. Clinical studies with bisphosphonates show an improvement in the control of hypercalcemia and a reduction in skeletal related morbidity with administration of pamidronate and zoledronic acid. Bisphosphonates have become the standard of care for osteolytic metastases associated with breast cancer. Recent data with zoledronic acid found that skeletal related morbidity may be reduced regardless of the radiographic picture of skeletal metastases. Thus, zoledronic acid may be valuable in osteolytic and osteoblastic disease as well as in disease with an osteolytic or osteoblastic radiographic appearance. In breast cancer with osteolytic disease, zoledronic acid may be more effective than pamidronate in reducing skeletal morbidity and prolonging the time to first skeletal event.
Tina J. Hieken, Mariana B. Sadurní, Enrica Quattrocchi, Ajdin Kobic, Sindhuja Sominidi-Damodaran, Lisette Meerstein, Jvalini T. Dwarkasing, Alina G. Bridges, and Alexander Meves
Background : The value of sentinel lymph node (SLN) surgery for patients with clinically node-negative T1b through T3 cutaneous melanomas is well-established. However, further precision in selecting patients for SLN surgery would be desirable as
-accreditation rate to the mid accreditation and post accreditation. Methods : Patients met the following criteria: The treating physicians were members of the unit no arm of the care was external; they underwent a combination therapy of surgery; systemic treatment
Christopher E. Desch
Christopher John Hughes, Thom Loree, Mark Burke, Michael Nagai, Nabil Alam, Daniel Ford, and James Zemer
-escalation strategies for curative therapy include the use of induction chemotherapy, prior to response-driven therapy, such as surgery or modified concurrent chemo-radiation. As yet there are no published data on the use of liquid biopsy in induction chemotherapy based
Rosalyn A. Juergens and Arlene Forastiere
Edited by Kerrin G. Robinson
controlled trial . Lancet 2002 ; 359 : 1727 – 1733 . 6. Burmeister BH Smithers BM Gebski V . Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial . Lancet